These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20361185)

  • 1. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
    Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
    Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
    Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
    Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
    Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
    Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
    Gabitzsch ES; Xu Y; Balcaitis S; Balint JP; Jones FR
    Cancer Gene Ther; 2011 May; 18(5):326-35. PubMed ID: 21233857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
    Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
    Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
    Gabitzsch ES; Xu Y; Balint JP; Balcaitis S; Sanders-Beer B; Jones FR
    Vaccine; 2011 Oct; 29(45):8101-7. PubMed ID: 21864618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
    Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
    Balint JP; Gabitzsch ES; Rice A; Latchman Y; Xu Y; Messerschmidt GL; Chaudhry A; Morse MA; Jones FR
    Cancer Immunol Immunother; 2015 Aug; 64(8):977-87. PubMed ID: 25956394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
    Quiroga D; Aldhamen YA; Godbehere S; Harding L; Amalfitano A
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28381403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
    Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
    J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
    Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
    Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
    Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
    J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
    Ji L; Bouvet M; Price RE; Roth JA; Fang B
    Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
    Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
    Peruzzi D; Dharmapuri S; Cirillo A; Bruni BE; Nicosia A; Cortese R; Colloca S; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2009 Feb; 27(9):1293-300. PubMed ID: 19162112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
    Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
    Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.
    Abe S; Okuda K; Ura T; Kondo A; Yoshida A; Yoshizaki S; Mizuguchi H; Klinman D; Shimada M
    J Gene Med; 2009 Jul; 11(7):570-9. PubMed ID: 19391169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.